Li et al. reported that the GPR40/120 agonist GW9508 improves hepatic steatosis in mice fed a high-cholesterol diet and inhibits LXR ligand-induced expression of lipogenic enzymes in HepG2 cells [12]. Here, FFAR1 is linked to fatty liver disease.